T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics.

about

Therapeutic Antibodies for Myeloid Neoplasms-Current Developments and Future Directions.Rationale for Combining Bispecific T Cell Activating Antibodies With Checkpoint Blockade for Cancer Therapy Expanding the Boundaries of Biotherapeutics with Bispecific Antibodies

P2860

Q55354182-DD30569C-2951-4B0B-8373-D1098E030A4C Q56890857-F0934942-794C-4520-897A-6D86BBCC7D8F Q58724935-BE11CC50-FE93-4BE0-9FCF-E7F4C6E9615E

P2860

T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics.

Item

http://www.wikidata.org/entity/Q47570404

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics.

@en

T cell engaging bispecific antibody

@nl

type

Item

label

T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics.

@en

T cell engaging bispecific antibody

@nl

prefLabel

T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics.

@en

T cell engaging bispecific antibody

@nl

P1476

T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics.

@en

P2093

N V Cheung

http://www.w3.org/2001/XMLSchema#string

Z Wu

http://www.w3.org/2001/XMLSchema#string

P2860

Highly efficient elimination of colorectal tumor-initiating cells by an EpCAM/CD3-bispecific antibody engaging human T cells

Perforin pores in the endosomal membrane trigger the release of endocytosed granzyme B into the cytosol of target cells.

Continuous cultures of fused cells secreting antibody of predefined specificity

Ways to enhance lymphocyte trafficking into tumors and fitness of tumor infiltrating lymphocytes

Bispecific antibodies

Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1.

Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

Alternative molecular formats and therapeutic applications for bispecific antibodies

Two new trifunctional antibodies for the therapy of human malignant melanoma

P304

161-175

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.PHARMTHERA.2017.08.005

http://www.w3.org/2001/XMLSchema#string

P478

182

http://www.w3.org/2001/XMLSchema#string

P577

2017-08-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28834699

http://www.w3.org/2001/XMLSchema#string

P932

5785550

http://www.w3.org/2001/XMLSchema#string

T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics.

about

P2860

P2860

T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698

P932